威尔明顿眼科中心推出经 FDA 批准的用于治疗青光眼和眼高压的 iDose® TR，由范德法特博士担任首位植入者。 Wilmington Eye introduces FDA-approved iDose® TR for glaucoma and ocular hypertension, with Dr. van der Vaart as the first implanter.

威尔明顿眼科中心现提供 iDose® TR，一种经 FDA 批准的治疗青光眼和眼高压的新型药物，可降低眼压。 Wilmington Eye is now offering iDose® TR, a new FDA-approved treatment for glaucoma and ocular hypertension, to reduce eye pressure. iDose TR 直接在眼内提供长期、持续的药物治疗。 iDose TR provides long-duration, continuous drug therapy directly inside the eye. 青光眼专家范德法特博士成为第一位植入该设备的医生，该设备可以帮助患者更好地控制与青光眼相关的升高的眼压。 Dr. van der Vaart, a glaucoma specialist, becomes the first doctor to implant the device, which helps patients take better control of elevated eye pressure associated with the conditions.